Cough Syrup Deaths: ED Raids Shree Ram Pharma Units in Chennai — Over 20 Children Dead Linked to ‘Coldrif’ Syrup
ED Investigation Uncovers Major Irregularities
T
he Enforcement Directorate (ED) has initiated a large-scale probe into Shree Ram Pharma over irregularities in its export operations of ‘Coldrif’ cough syrup. The raids, conducted under the Prevention of Money Laundering Act (PMLA), targeted seven sites across Chennai. The company is accused of exporting substandard formulations to African and Southeast Asian nations, allegedly resulting in the deaths of more than twenty children in Gambia and Uttar Pradesh.
Forensic experts detected excessive levels of diethylene glycol and ethylene glycol—industrial solvents known to cause kidney failure. ED officers seized digital data, bank records, and ingredient lists. The firm’s director, senior chemist, and key distributors are being questioned.
Authorities cited repeated violations flagged by the Central Drugs Standard Control Organisation (CDSCO) since 2011. Despite warnings, the firm failed to upgrade its safety protocols, said Tamil Nadu’s Food and Drug Administration (TNFDA).
Officials suspect rejected export stock was repackaged for domestic sale under fake labels, worsening the crisis caused by the tainted batches.
Link to Global Cough Syrup Tragedy
T
he “Coldrif” case drew international attention when the World Health Organization (WHO) issued an alert on contaminated Indian syrups. Tests confirmed the presence of industrial-grade chemicals unfit for consumption. Multiple nations banned imports pending investigation.
India’s Health Ministry coordinated with the Directorate General of Foreign Trade (DGFT) and ED, stating a zero-tolerance policy for negligence that endangers lives. The ministry emphasized that accountability would be enforced both at company and regulatory levels.
Pharma experts warned this scandal could harm India’s image as the “pharmacy of the world.” Calls for tighter monitoring of small-scale exporters are gaining momentum. They argue that micro manufacturers often lack adequate quality infrastructure.
Parents of victims in Gambia appealed for compensation and justice. India’s External Affairs Ministry assured full cooperation with global authorities to uphold transparency.
Industry Shock and Government Response
T
he revelations triggered nationwide outrage. Activists demanded recall of all Shree Ram Pharma products until safety verification is complete. Several states began random testing of similar syrups to avoid repetition.
ED officials traced ₹30 crore in suspicious transactions between the company and overseas buyers, suspecting money laundering. The findings may expand the probe into parallel financial networks.
India’s Commerce Ministry plans new export compliance norms. Officials fear recurring scandals could impact pharmaceutical diplomacy and trade credibility.
The Tamil Nadu government sealed three of the company’s units, while police filed charges of criminal negligence. Arrests are expected soon.
Preventive Action and Future Policy
A
special joint task force comprising ED, CDSCO, and CBI has been formed to trace chemical suppliers. Early findings link the toxic materials to an unregistered Gujarat vendor. Health Minister Dr. Mansukh Mandaviya confirmed a nationwide audit of cough syrup makers is underway.
The Centre is considering criminal liability clauses for pharmaceutical negligence causing deaths. This step aims to deter repeat offenders and restore public confidence in India’s drug ecosystem.
Experts note that the case will likely influence future pharmaceutical laws and redefine India’s role as a trusted global supplier.
Post a Comment